Showing results (101-110 of 183) with videos related to
Sort By:
Pageof 19
The Lancet. Oncology|April 23, 2013
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 studySandra M Swain, Sung-Bae Kim, Javier Cortés, et al.Frontiers in Oncology|September 28, 2020
Prevalence of Phosphatidylinositol-3-Kinase (PI3K) Pathway Alterations and Co-alteration of Other Molecular Markers in Breast CancerKatia Khoury, Antoinette R Tan, Andrew Elliott, et al.The New England Journal of Medicine|February 19, 2015
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancerSandra M Swain, José Baselga, Sung-Bae Kim, et al.Journal of the National Cancer Institute|September 28, 2017
Long-term Peripheral Neuropathy in Breast Cancer Patients Treated With Adjuvant Chemotherapy: NRG Oncology/NSABP B-30Hanna Bandos, Joy Melnikow, Donna R Rivera, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2008
Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancerChia C Portera, Janice M Walshe, Douglas R Rosing, et al.Cancer Medicine|May 2, 2013
Assessment of diagnosis of inflammatory breast cancer cases at two cancer centers in Egypt and TunisiaCatherine Schairer, Amr S Soliman, Sherif Omar, et al.The Oncologist|February 12, 2020
De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs RegistryDebu Tripathy, Adam Brufsky, Melody Cobleigh, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 11, 2002
Microvessel density, expression of estrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast cancerNicole J McCarthy, Xiaowei Yang, Ilona R Linnoila, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2018
Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERsSara A Hurvitz, Joyce O'Shaughnessy, Ginny Mason, et al.Cancers|October 27, 2022
Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled AnalysisSandra M Swain, Harrison Macharia, Javier Cortes, et al.Pageof 19